Cycurion shares tumble 18% on Nasdaq delisting notice

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights

Cycurion, Inc. received a delisting determination from Nasdaq for failing to meet the $1.00 minimum bid price requirement for 31 consecutive business days. Following the news, shares dropped 18.36% in after-hours trading to $0.38. The company, which is ineligible for the standard 180-day compliance period due to a 1-for-30 reverse stock split in October 2025, intends to appeal the decision by July 17, 2026. While the appeal process stays the suspension, there is no guarantee of continued listing. Despite the regulatory challenge, the company reports an annual revenue run rate exceeding $28 million and maintains that operations remain unaffected.

powered bylight_fuzz_icon
45781965

*this image is generated using AI for illustrative purposes only.

Cycurion, Inc. shares fell 18.36% to $0.38 in after-hours trading Thursday after the cybersecurity company disclosed it received a delisting determination letter from The Nasdaq Stock Market LLC for failing to meet the minimum bid price requirement. The stock had closed the regular session up 2.04% at $0.47. The determination, dated July 10, 2026, states that the closing bid price of Cycurion’s common stock was below the $1.00 per share minimum for 31 consecutive business days from May 26, 2026, through July 9, 2026. Consequently, Nasdaq determined that the company does not comply with Nasdaq Listing Rule 5550(a)(1).

Because Cycurion effected a 1-for-30 reverse stock split on October 27, 2025, it is ineligible for the customary 180-calendar day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Without a timely hearing request, trading was expected to be suspended at the opening of business on July 21, 2026. The company intends to file a hearing request before the July 17, 2026 deadline. A timely request will stay the suspension of Cycurion’s securities and the filing of a Form 25-NSE pending the Hearings Panel's decision. There is no assurance that the Hearings Panel will grant continued listing or that the company will regain compliance.

Trading Metrics and Strategic Status

Cycurion has a market capitalization of approximately $5.4 million, with a 52-week high of $16.03 and a 52-week low of $0.40. The stock has declined 95.97% over the past 12 months. Cycurion’s Board of Directors and management have determined not to pursue a reverse stock split at this time. The Board continues to evaluate all available options for regaining compliance, including actions related to the hearing process. The company emphasized that this matter does not impact its operations or strategic execution.

Kevin Kelly, Chairman and Chief Executive Officer of Cycurion, stated that the company is fully prepared for the Nasdaq Hearings Panel process. He noted that Cycurion is developing a data-driven record of trading activity supported by internal analysis and external market data to ensure the market valuation reflects underlying fundamentals.

Financial Metrics and Outlook

Cycurion reported that its business momentum remains strong, with an annual revenue run rate exceeding $28 million. This performance is supported by contracted backlog and a growing pipeline of opportunities, including recently secured multi-year agreements. The company continues to generate revenue growth through organic expansion, strategic acquisitions, and long-term customer contracts.

Key Financial and Operational Details
Annual Revenue Run Rate Exceeding $28 million
Market Capitalization Approximately $5.4 million
52-Week High $16.03
52-Week Low $0.40
Listing Rule Violation Nasdaq Listing Rule 5550(a)(1)
Compliance Period Ineligibility Nasdaq Listing Rule 5810(c)(3)(A)(iv)
Reverse Stock Split Date October 27, 2025
Hearing Request Deadline July 17, 2026

Hearings are typically scheduled approximately 30 to 45 days following the company’s request. The Nasdaq Hearings Panel has broad discretion to consider all relevant factors in determining whether to grant continued listing or an extension. Cycurion is actively preparing its materials, including forensic analysis and engagement with external advisors, to support this process.

If the Nasdaq Hearings Panel denies continued listing, what alternative trading venues or over-the-counter markets might Cycurion utilize?

How will the company's inability to pursue another reverse stock split impact its strategy to regain the $1.00 minimum bid price?

What specific operational milestones or revenue targets must Cycurion hit to naturally lift its stock price without corporate actions?

like16
dislike

Cycurion rejects 7-for-1 reverse split citing market abuse risks

scanx
Reviewed by
Shraddha JScanX News Team
Key Highlights

Cycurion declined a 7-for-1 reverse stock split after determining it would not protect shareholders and could expose them to substantial risk due to market manipulation. The company is focusing on business growth, having acquired Digital Ally and Secuvant, reaching an annual revenue run rate of approximately $28 million. A forensic review revealed irregular trading patterns, including spoofing and excessive short sales, prompting the company to contact NASDAQ.

powered bylight_fuzz_icon
44577466

*this image is generated using AI for illustrative purposes only.

Cycurion has determined that a 7-for-1 reverse stock split is not in the best interest of shareholders at this time, citing substantial risks of market manipulation and irregular short selling. The decision follows a forensic review of trading activity, which the company suggests indicates market abuse. Management stated that a reverse split would not resolve underlying issues and would divert focus from building the business through sustainable performance. The company intends to pursue parties responsible for improper trading identified in its review.

Business Growth and Strategic Acquisitions

The company emphasized its focus on expanding operations and increasing profitability. Over the past year, Cycurion completed two strategic acquisitions: Digital Ally, contributing approximately $5.1 million in revenue, and Secuvant, contributing approximately $2.5 million. Organic revenue grew to approximately $15.5 million, lifting the annual revenue run rate to approximately $28 million. The firm also secured a new ten-year contract valued at $58 million and built approximately $8 million of contracted backlog.

Metric Value
Digital Ally Revenue ~$5.1 million
Secuvant Revenue ~$2.5 million
Organic Revenue ~$15.5 million
Annual Revenue Run Rate ~$28 million
New Contract Value $58 million
Contracted Backlog ~$8 million

Analysis of Reverse Stock Split Risks

Management analyzed the potential impact of a reverse split based on trading patterns from 2025. If a 7-for-1 split had been announced while the stock traded around $0.60, the implied post-split price would have been approximately $4.20. However, historical data suggests the stock could have been driven down to an effective range of $1.20 to $1.50, leaving it vulnerable to falling below $1.00 again. The Board concluded that the risk of reducing shareholder ownership without achieving stable price support was too high.

Evidence of Suspected Market Abuse

Cycurion's review revealed trading activity it deems inconsistent with fair and orderly markets. In October 2025, approximately 89.9 million shares changed hands in a single session against a float of roughly 86.5 million shares, representing more than 100% turnover. On March 16, 2026, the stock fell approximately 45% intraday, triggering the Regulation SHO Rule 201 short-sale circuit breaker. Despite restrictions, records show a surge in short sales marked as "short exempt" on March 16 and 17. The company also identified order patterns consistent with "spoofing," involving rapid sequencing of cancellations to create false impressions of supply and demand. Cycurion is in contact with NASDAQ regarding these findings.

What specific legal actions or regulatory complaints does Cycurion plan to file against the parties identified in the forensic review?

How will the company allocate resources to pursue market abusers while simultaneously managing the integration of recent acquisitions?

What operational strategies will management implement to convert the new $58 million contract and backlog into realized revenue to stabilize the stock price organically?

like17
dislike

More News on Cycurion Inc